Skylar Jeremias

Releuko, a filgrastim biosimilar developed by Kashiv Biosciences and Amneal Pharmaceuticals, becomes the third filgrastim biosimilar to be approved by the FDA.

Robert Gabbay, MD, PhD, of the American Diabetes Association (ADA), talks about the impact that finerenone could have on patients with kidney disease and diabetes.

Thermo Fisher Scientific will begin accepting submissions for grant proposals focusing on molecular profiling in cancer spaces, where applicants could receive up to $200,000 in funding.

Biocon Biologics announced that it will be acquiring Viatris’ biosimilars portfolio for close to $3 billion.

A study showed that patients with multiple myeloma (MM) deal with physical, social, and emotional pain and that physicians did not fully comprehend the extent to which patients experienced pain, suggesting improved communication between parties is warranted.

Health care providers need to foster a greater push for physical activity as a part of survivorship care for patients with multiple myeloma (MM), investigators concluded after finding that only 25% of patients were active.

Julie M. Reed, the new executive director of the Biosimilars Forum, offers her opinion on how interchangeability will impact US biosimilar uptake now that the FDA has given the designation to 2 biosimilars.

Robert Gabbay, MD, PhD, of the American Diabetes Association (ADA), breaks down the reasoning behind the organization's decision to add Bayer's Kerendia (finerenon) as a recommended drug for kidney disease prevention.

The COVID-19 pandemic has resulted in significant disparities in mortality and made ever-present systemic issues worse for historically underserved communities, signaling that greater efforts to address social determinants of health (SDOHs) are needed now more than ever.

Access to digital health tools to improve patient outcomes and quality of life are lacking among patients with multiple myeloma (MM) who are elderly, at risk of relapse, or live in rural communities, suggesting more tools and guidelines are needed for these populations.

Robert Gabbay, MD, PhD, of the American Diabetes Association, explains why a section on chronic kidney disease management was added to the ADA's 2022 standard of care guidelines.

Two cancer-related micro-RNAs could serve as prognostic biomarkers for multiple myeloma bone disease as lower levels were associated with lower overall survival rates, investigators concluded.

Foundation Medicine’s circulating tumor DNA (ctDNA) detection and monitoring assay, FoundationOne Tracker, was granted a Breakthrough Device Designation from the FDA, streamlining the approval and review processes to give patients and providers earlier access to the device.

Although the COVID-19 pandemic has led to mass slowdowns in drug approvals and biosimilar launches, 2021 signaled a stronger focus on biosimilars going forward, with new regulatory bills and a crackdown on anticompetitive practices.

The organization announced a partnership with over 1000 nephrology providers to help implement CMS’ new Kidney Care Choices models beginning this year.

Robert A. Gabbay, MD, PhD, chief scientific and medical officer at the American Diabetes Association, shares his thoughts on long COVID-19 among those with type 2 diabetes and the rise of new-onset cases of type 1 diabetes throughout the pandemic.

Adding risk factors specific to patients with chronic kidney disease (CKD) to risk prediction models for cardiovascular disease (CVD) could improve risk prediction capabilities for a population of patients often subject to invasive diagnostic procedures, investigators concluded.

Megan Olsen, MPH, principal at Avalere, explains how payers are attempting to get around cost concerns associated with expensive cell and gene therapies.

Researchers concluded that incident corneal adverse events in patients with multiple myeloma (MM) carry a low clinical and economic burden compared with total all-cause costs and MM-related per-patient-per-month costs.

Patients with multiple myeloma (MM) who have been fully vaccinated against COVID-19 were found to have an increased risk of breakthrough infections and related hospitalizations, signaling the need for more studies and precautions.

Patients with chronic kidney disease (CKD) and their caregivers who have participated in CKD research shared factors that may encourage or discourage others from enrolling in clinical studies, highlighting the ways that investigators can better involve patients in research.

Megan Olsen, MPH, principal at Avalere, explores the challenges that arise for Medicaid plans when providers choose to prescribe a cell or gene therapy.

Kathy Oubre, MS, chief operating officer of Pontchartrain Cancer Center, talks about how biosimilars have been able to help patients avoid financial toxicity related to oncology care costs.

Robert Gabbay, MD, PhD, of the American Diabetes Association (ADA), discusses the development process for the section of ADA guidelines that touches on chronic kidney disease (CKD) management in patients with diabetes.

Early mortality rates for patients with multiple myeloma (MM) have significantly decreased over the last 20 years; however, more efforts are needed for older patients, who still experience high rates.

Robert A. Gabbay, MD, PhD, chief scientific and medical officer at the American Diabetes Association, discusses some of the challenges of treating pediatric patients with type 1 or type 2 diabetes.

A large international real-world analysis revealed the extent to which the COVID-19 pandemic has impacted the global population of patients with multiple myeloma (MM) and the ability for providers to help patients manage the condition.

About half of all patients with multiple myeloma (MM) receiving corticosteroid-based chemotherapy were found to have adrenal insufficiency (AI), while identifying suspicious symptoms of AI may be a key component to its detection in this population.

Megan Olsen, MPH, principal at Avalere, provides a comprehensive overlook into the many ways that the COVID-19 pandemic has impacted the cell and gene therapy space.

The American Diabetes Association (ADA) has added a new section to their 2022 Standard of Care guidelines to assist clinicians in managing and preventing the presence of chronic kidney disease and related complications in patients with diabetes.